SCHEMBL2369017

SCHEMBL2369017

CC(C)(C)c1ccc(-c2csc3ncnc(Cl)c23)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.71
MAPT P10636 5/20 0.71
SMN1; SMN2 Q16637 4/20 0.71
KMT2A Q03164 4/20 0.71
LMNA P02545 4/20 0.68
ALDH1A1 P00352 4/20 0.68
NPSR1 Q6W5P4 1/20 0.67
KDM4E B2RXH2 1/20 0.49
FGFR1 P11362 2/20 0.44
DAPK3 O43293 1/20 0.44
PRKD3 O94806 1/20 0.44
MAP4K4 O95819 1/20 0.44
ABL1 P00519 1/20 0.44
NTRK1 P04629 1/20 0.44
LCK P06239 1/20 0.44
CSF1R P07333 1/20 0.44
RET P07949 1/20 0.44
MET P08581 1/20 0.44
PDGFRB P09619 1/20 0.44
PDGFRA P16234 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2368917 0.84 MAPT (0.77) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL2369317 0.83 MAPT (1.00) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL2369140 0.81 SMN1; SMN2 (1.00) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL1604911 0.81 SMN1; SMN2 (1.00) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL3163635 0.80 SMN1; SMN2 (0.77) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL2368374 0.80 SMN1; SMN2 (0.77) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL2253337 0.80 MAPT (1.00) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL2368793 0.79 LMNA (0.55) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL2368934 0.77 SMN1; SMN2 (0.67) HTTMAPTSMN1; SMN2KMT2ALMNA
SCHEMBL2369484 0.75 HTT (0.41) HTTMAPTSMN1; SMN2KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 HTT 543/4885MAPT 2978/4885SMN1; SMN2 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.